São Paulo government paid $2 million for cannabis-based medicine
In Brazil, health is a fundamental right granted by the Brazilian Universal Health System (SUS) protected by the Constitution of 1988. SUS is composed of a set of health services and actions. Sao Paulo’s government spent about $2 million for medicine based on cannabis to treat epilepsy and other multiple diseases. 78 patients are already being treated while 123 authorizations have been met.
São Paulo’s government has already spent $2 million (R$ 8,913,109.59) for cannabis-based medicine.
The amount was paid for the treatment of 201 patients. These patients went to court to obtain the medication by SUS (Brazil’s publicly funded health care system).
The latest CBD & Cannabis updates are now at your fingertips, with notifications and fresh information offered by our companion CBD News App.
Stay up-to-date with marijuana stocks for investments, global market, cannabis legalization and more.
Cannabis – a remedy for serious diseases
According to folder data, 123 authorizations have already been approved, at a cost of $1 million (R$ 5,812,634.50) and 78 patients are already being treated.
According to the secretary, the most common diagnosis among patients treated with cannabis is epilepsy, representing 70% of cases.
There are also patients with chronic pain, Parkinson’s disease and infantile cerebral palsy, among other diseases.
The figures do not include expenses with lawyers and the time invested by public defenders in these lawsuits.
A bill to access cannabis medicine
In order to clear the judicialization in the supply of cannabis drugs by the SUS, the state congressman Caio França (PSB) filed a bill that provides easy access to cannabis-based drugs by the Unified Health System.
A public hearing was held in São Paulo Parliament. On that occasion, several suggestions were made to the original text.
Victor Hugo Costa Travassos, the coordinator of pharmaceutical-assistance to the Health Secretariat, warned: “I can’t provide the medication without federal legislation.”
Anvisa is promoting a healthy population
Caio França assured that this is only a legal issue, “but I am very sure that our law does not advance competencies that are of the Congress or of Anvisa itself”.
“Anvisa’s own director-president praised the Law Project. “I do not create any new medicine, as I am not involved in the cultivation agenda, I simply extend Anvisa’s understanding of facilitating the import of individuals to the government of the State of São Paulo,” he said.
“I’m giving the regulations that Victor Hugo is asking to make importing easier, with budget forecast to reduce spending and increase the number of people served, I understand that this law is important,” concluded the deputy.
The project is likely to be approved this year
He is expecting the bill to be adopted this year. “I believe that prejudice is much more about a lack of information.”
“The public hearing that I made, the recorded testimonies of doctors, especially family members, will be decisive in the approval of this proposal. I trust in the common sense and balance of my colleagues”.
The parliamentarian answered about project approval: “The judicialization is responsible for about 30% of expenditures. So if we are at almost $2 million (R$ 10 million) in the current situation, we are talking about $710,000 (R$ 3 million) spent only on judicialization.”
“So it’s just a perspective. As I imagine it will increase from our project, it is natural that what will be saved will also increase, if we dispense with the judicial decision”.
(Featured image by Wild0ne via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in SECHAT, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Consolidation of the Fintech Sector Reinforces Mastercard’s Commitment to the Sector
Mauricio Schwartzmann, CEO of Mastercard Mexico, stressed that the firm's involvement with financial technology is long-term and goes hand in...
Canal de Isabel II Accelerates Towards Energy Self-Consumption
Canal de Isabel II will switch from the then state-of-the-art Pelton turbines of 1913 to producing green hydrogen from reclaimed...
Dogecoin: Doge Whales Return Due to Bullish Metrics
In the short term, Dogecoin is encountering its first major resistance at $0.075, although a larger obstacle lies at $0.08....
Exit for Kippy, which Had Closed Two Equity Crowdfunding Rounds
Kippy recently participated in the third batch of the A-Road acceleration and fundraising program which, through ongoing training and mentorship...
Laminar Pharma Opens a €5 Million Round through Capital Cell
Looking ahead to 2024, the group plans to reach break-even, when the European Medicines Agency approves its drug against glioblastoma,...
Cannabis6 days ago
Where Do Cannabis Users Buy Cannabis From: New Frontier Data Study
Biotech2 weeks ago
Boehringer Ingelheim Invests 46 Million in R&D in 2022 in Spain
Biotech1 day ago
Netpharmalab Reaches €3 Million in 2022 and Anticipates a 16% Increase in 2023
Biotech1 week ago
Almirall Projects to Reach Revenues of €1 Billion in 2025